Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 7-20

  Jacob, Naduparambil K ^a   Cooley, James V ^a   Shirai, Katsuyuki ^a   Chakravarti, Arnab ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Mitosis; Radiation; Survivin; Survivin splice variants

Indexed keywords

AURORA B KINASE; CASPASE 3; CELL PROTEIN; SURVIVIN; SURVIVIN 2A; SURVIVIN 2B; SURVIVIN 3B; SURVIVIN DELTA EX3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; CYTOKINESIS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN FUNCTION;

EID: 84861354071     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S28147     Document Type: Article

References (40)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-921.
2. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 2007;131(2):271-285.
3. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007;8(10):798-812.
4. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol. 2006;173(6):833-837.
5. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):21-32.
6. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842-854.
7. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114(8):1117-1127.
8. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-584.
9. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315-5320.
10. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res. 2002;93(9):1057-1062.
11. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314(3):902-907.
12. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4(1):11.
13. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24(12):1994-2007.
14. Conway EM, Pollefeyt S, Cornelissen J, et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood. 2000;95(4):1435-1442.
15. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4(3):174-191.
16. Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004;23(45):7545-7551.
17. Wuttig D, Kunze D, Fuessel S, et al. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNAmediated in vitro inhibition? Int J Oncol. 2007;30(6):1317-1324.
18. Ling X, Yang J, Tan D, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer. 2005;49(3):353-361.
19. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, Sweep FC. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem. 2006;52(9):1693-1700.
20. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92(2):212-216.
21. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer. 2005;92(2):359-365.
22. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21(17):2613-2622.
23. Ling X, Cheng Q, Black JD, Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem. 2007;282(37):27204-27214.
24. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin- deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097-6102.
25. Knauer SK, Bier C, Schlag P, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle. 2007;6(12):1502-1509.
26. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86(5):737-743.
27. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer. 2002;100(1):30-36.
28. Cheng Z, Hu L, Fu W, Zhang Q, Liao X. Expression of survivin and its splice variants in gastric cancer. J Huazhong Univ Sci Technolog Med Sci. 2007;27(4):393-398.
29. Yamada Y, Kuroiwa T, Nakagawa T, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg.2003;99(4):738-745.
30. Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev. 2009;32(4):308-313.
31. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med. 2009;23(2):285-291.
32. De Maria S, Pannone G, Bufo P, et al. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(1):107-116.
33. Futakuchi H, Ueda M, Kanda K, Fujino K, Yamaguchi H, Noda S. Transcriptional expression of survivin and its splice variants in cervical carcinomas. Int J Gynecol Cancer. 2007;17(5):1092-1098.
34. He XF, Wen DG, Hou JQ, He J, Cen JN. Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance. Ai Zheng. 2009;28(11):1209-1213.
35. Nakano J, Huang C, Liu D, et al. The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer. 2008;98(6):1109-1117.
36. Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol J. 2009;6(2):101-108.
37. Vegran F, Boidot R, Oudin C, Def rain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene. 2007;26(2):290-297.
38. Uren AG, Beilharz T, O'Connell MJ, et al. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci U S A. 1999;96(18):10170-10175.
39. Speliotes EK, Uren A, Vaux D, Horvitz HR. The survivin-like C. Elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell. 2000;6(2):211-223.
40. Deguchi M, Shiraki K, Inoue H, et al. Expression of survivin during liver regeneration. Biochem Biophys Res Commun. 2002;297(1):59-64.